Bevacizimab
4 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma (NCT04143425) | Ho Sung Kim | 2020-02-06 |
| Chronic Inflammation, Plasma Proteins Signature, Survival Outcomes and Clinical Response, in Patients Receiving Bevacizumab Combined With Oxaliplatin-based Chemotherapy (Bev/OX) or Bevacizumab Combined With Irinotecan-based Chemotherapy (Bev/IRI) (NCT07241403) | Second Affiliated Hospital of Nanchang University | 2018-01-01 |
Track Bevacizimab automatically
Every clearance here is in the API, with alerts when new ones post.